Ingalls & Snyder LLC Supernus Pharmaceuticals, Inc. Transaction History

Ingalls & Snyder LLC

  • $2.56 Billion
  • Q3 2024

A detailed history of Ingalls & Snyder LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ingalls & Snyder LLC holds 11,500 shares of SUPN stock, worth $409,400. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,500
Previous 21,688 46.98%
Holding current value
$409,400
Previous $580,000 38.1%
% of portfolio
0.01%
Previous 0.02%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$25.77 - $35.16 $262,544 - $358,210
-10,188 Reduced 46.98%
11,500 $359,000
Q2 2024

Jul 31, 2024
SELL
$25.99 - $33.85 $25,990 - $33,850
-1,000 Reduced 4.41%
21,688 $580,000
Q4 2023

Jan 29, 2024
SELL
$22.72 - $29.68 $45,440 - $59,360
-2,000 Reduced 8.1%
22,688 $657,000
Q3 2023

Nov 02, 2023
SELL
$27.57 - $32.91 $314,298 - $375,173
-11,400 Reduced 31.59%
24,688 $681,000
Q2 2023

Jul 27, 2023
SELL
$29.91 - $38.73 $2,991 - $3,872
-100 Reduced 0.28%
36,088 $1.09 Million
Q1 2023

May 09, 2023
SELL
$34.93 - $42.03 $139,720 - $168,120
-4,000 Reduced 9.95%
36,188 $1.31 Million
Q4 2021

Feb 11, 2022
SELL
$26.37 - $34.22 $785,826 - $1.02 Million
-29,800 Reduced 42.58%
40,188 $1.17 Million
Q3 2021

Oct 27, 2021
SELL
$23.54 - $31.39 $54,142 - $72,197
-2,300 Reduced 3.18%
69,988 $1.87 Million
Q4 2020

Jan 27, 2021
BUY
$17.7 - $25.81 $15,930 - $23,229
900 Added 1.26%
72,288 $1.82 Million
Q3 2020

Oct 21, 2020
BUY
$20.2 - $25.05 $4,040 - $5,010
200 Added 0.28%
71,388 $1.49 Million
Q2 2020

Jul 31, 2020
BUY
$17.09 - $24.89 $8,545 - $12,445
500 Added 0.71%
71,188 $1.69 Million
Q4 2019

Jan 15, 2020
SELL
$19.93 - $29.13 $2.08 Million - $3.04 Million
-104,200 Reduced 59.58%
70,688 $1.68 Million
Q3 2019

Oct 16, 2019
BUY
$25.47 - $33.37 $249,606 - $327,026
9,800 Added 5.94%
174,888 $4.81 Million
Q2 2019

Jul 11, 2019
SELL
$29.96 - $38.87 $164,780 - $213,785
-5,500 Reduced 3.22%
165,088 $5.46 Million
Q1 2019

Apr 11, 2019
SELL
$32.77 - $41.99 $16,385 - $20,995
-500 Reduced 0.29%
170,588 $5.98 Million
Q4 2018

Jan 24, 2019
SELL
$30.84 - $49.51 $3,084 - $4,951
-100 Reduced 0.06%
171,088 $5.68 Million
Q2 2018

Aug 10, 2018
SELL
$44.1 - $59.85 $103,502 - $140,467
-2,347 Reduced 1.35%
171,188 $10.2 Million
Q1 2018

Apr 17, 2018
SELL
$37.15 - $46.9 $74,300 - $93,800
-2,000 Reduced 1.14%
173,535 $7.95 Million
Q4 2017

Jan 19, 2018
SELL
$36.4 - $42.6 $3,640 - $4,260
-100 Reduced 0.06%
175,535 $7 Million
Q3 2017

Oct 20, 2017
BUY
$36.75 - $49.65 $6.45 Million - $8.72 Million
175,635
175,635 $7.03 Million

Others Institutions Holding SUPN

# of Institutions
281
Shares Held
60.6M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Ingalls & Snyder LLC Portfolio

Follow Ingalls & Snyder LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email